(NewsNation) — A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England Journal of Medicine on May 11, the study attempted to analyze the ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Participants who received tirzepatide, the active ingredient in Zepbound, also had greater reductions in waist size and more significant improvements in metabolic risk factors. Tirzepatide’s dual ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s obesity drug Zepbound lost nearly 50% more weight than those using rival Novo ...

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

As for this specific alternative, the weight loss results are “remarkable” so far, says Gitanjali Srivastava, MD, co-director ...

Zepbound (tirzepatide) is a brand-name injection prescribed for weight loss, weight management, and more. You may need to take Zepbound for several months to see the full effects of the drug for ...

Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...